Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

China flag China · Delayed Price · Currency is CNY
63.39
-0.41 (-0.64%)
Jul 30, 2025, 2:45 PM CST
-0.64%
Market Cap426.03B
Revenue (ttm)29.19B
Net Income (ttm)6.84B
Shares Out6.63B
EPS (ttm)1.09
PE Ratio58.46
Forward PE47.55
Dividend0.20 (0.32%)
Ex-Dividend DateMay 23, 2025
Volume93,373,741
Average Volume64,022,140
Open63.81
Previous Close63.80
Day's Range62.65 - 64.73
52-Week Range39.62 - 65.43
Beta0.36
RSI76.58
Earnings DateAug 21, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra... [Read more]

Sector Healthcare
Founded 1970
Employees 20,238
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600276
Full Company Profile

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial Statements

News

There is no news available yet.